Zacks Research Has Bearish Estimate for A Q1 Earnings

Agilent Technologies, Inc. (NYSE:A - Free Report) - Analysts at Zacks Research decreased their Q1 2025 earnings estimates for Agilent Technologies in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $1.27 per share for the quarter, down from their previous estimate of $1.38. The consensus estimate for Agilent Technologies' current full-year earnings is $5.56 per share. Zacks Research also issued estimates for Agilent Technologies' Q2 2025 earnings at $1.33 EPS, Q4 2025 earnings at $1.55 EPS, FY2025 earnings at $5.55 EPS, Q1 2026 earnings at $1.36 EPS, Q3 2026 earnings at $1.58 EPS and FY2026 earnings at $6.10 EPS.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.41 by $0.05. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The firm's quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the business posted $1.38 earnings per share.

Several other equities research analysts have also recently commented on A. TD Cowen boosted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a "buy" rating in a research report on Thursday, August 22nd. UBS Group increased their price target on Agilent Technologies from $141.00 to $150.00 and gave the company a "neutral" rating in a research report on Thursday, August 22nd. Bank of America lowered their price target on Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a research report on Friday. Evercore ISI increased their price objective on Agilent Technologies from $135.00 to $145.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating on the stock in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $143.36.

Agilent Technologies Stock Down 2.1 %

Shares of A traded down $2.99 during mid-day trading on Friday, hitting $137.92. 569,301 shares of the company's stock were exchanged, compared to its average volume of 1,718,176. The company has a 50-day simple moving average of $136.87 and a 200 day simple moving average of $136.60. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The company has a market cap of $39.63 billion, a PE ratio of 31.15, a P/E/G ratio of 4.48 and a beta of 1.07. Agilent Technologies has a 52 week low of $124.16 and a 52 week high of $155.35.

Hedge Funds Weigh In On Agilent Technologies

Several hedge funds and other institutional investors have recently modified their holdings of A. Massachusetts Financial Services Co. MA lifted its stake in shares of Agilent Technologies by 5.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company's stock valued at $1,952,832,000 after acquiring an additional 809,149 shares during the last quarter. FMR LLC boosted its stake in shares of Agilent Technologies by 62.2% during the third quarter. FMR LLC now owns 1,287,665 shares of the medical research company's stock valued at $191,193,000 after purchasing an additional 493,947 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Agilent Technologies in the third quarter valued at approximately $49,449,000. Marshall Wace LLP raised its holdings in Agilent Technologies by 48.6% in the 2nd quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company's stock valued at $124,073,000 after buying an additional 313,155 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Agilent Technologies by 63.3% during the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company's stock worth $87,075,000 after buying an additional 227,431 shares during the period.

Insider Activity

In other news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company's stock, valued at approximately $5,801,595. This represents a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Agilent Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.248 per share. This is a boost from Agilent Technologies's previous quarterly dividend of $0.24. The ex-dividend date is Tuesday, December 31st. This represents a $0.99 annualized dividend and a yield of 0.72%. Agilent Technologies's dividend payout ratio (DPR) is presently 21.27%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.